Progresses of VEGFR2 targeted ultrasound contrast imaging in diagnosis of breast cancer
10.13929/j.1003-3289.201806150
- Author:
Huan ZHANG
1
Author Information
1. Department of Ultrasound, West China Hospital, Sichuan University
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Contrast media;
Ultrasonography;
Vascular endothelial growth factor receptor
- From:
Chinese Journal of Medical Imaging Technology
2019;35(3):463-466
- CountryChina
- Language:Chinese
-
Abstract:
Tumor angiogenesis plays an important role in growth and metastasis of breast cancer. Vascular endothelial growth factor receptor 2 (VEGFR2) is over-expressed on tumor neo-angiogenesis endothelial cells. Ultrasound molecular imaging (USMI) is a new technology to identify the specific expression of vascular endothelial cells by targeted ultrasound contrast agent (tUCAs). A large number of experimental and preliminary clinical studies have demonstrated that USMI with VEGFR2 tUCAs could be used to diagnose breast cancer. The progresses of VEGFR2 targeted ultrasound contrast imaging in the diagnosis of breast cancer were reviewed in this article.
